Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of XZP-5955 in NTRK- or ROS1-positive advanced solid tumors
CTR20211858Phase 2Active
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XZP-5955 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), sponsored by Xuanzhu Biopharmaceutical. Started Dec 2021; status: active.
02
Drugs
XZP-5955
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20211858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211858.